Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag A new dual-antibody therapy showed strong, lasting responses in patients with rare, hard-to-treat multiple myeloma.

flag An off-the-shelf dual-antibody immunotherapy showed deep, lasting responses in patients with extramedullary multiple myeloma, a rare and aggressive form resistant to standard treatments, according to a Mayo Clinic study published in the New England Journal of Medicine. flag The therapy, which targets two proteins on cancer cells, is immediately available and does not require custom preparation. flag Early results indicate significant tumor reduction and prolonged remission in some patients, offering new hope for those with limited options. flag The approach, still in early trials, could transform care for this difficult-to-treat subgroup.

5 Articles

Further Reading